Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease

Abstract

Our model supports implementing more restrictive guidelines for palivizumab prophylaxis. Palivizumab was cost-effective for some infants in an analysis that accounted for increased risk of severe asthma following respiratory syncytial virus infection.